Researchers at GIS and MPIMG discovered a molecular network in human embryonic stem cells that activates the ERK pathway, causing cells to respond by activating genetic information. The network also silences genetic information through ELK1, maintaining the cell's undifferentiated state.
A*STAR and Cytos have initiated a Phase 1 clinical trial for Singapore's first H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle (VLP) technology. The vaccine aims to provide an effective means of combating influenza epidemics and pandemics in Singapore and the ASEAN region.
A*STAR and Veredus have developed VereTrop, the world's first biochip to diagnose multiple tropical infectious diseases from one blood sample. The portable test kit can rapidly detect diseases like dengue fever, malaria, and chikungunya with high accuracy.
Researchers at A*STAR's Institute of Molecular and Cell Biology have decoded the genome of the African coelacanth, revealing genetic changes that enabled aquatic animals to transition to life on land. The study provides valuable insights into the evolutionary history of the species and its adaptations.
The joint research collaboration aims to develop new approaches to tackle emerging infectious diseases in the Asia-Pacific region. The project will focus on designing treatments and vaccines for tuberculosis, predicting patients at risk of severe dengue, and developing improved vaccines against virus diseases.
VeriStem Technologies has developed an antibody that selectively targets and kills undifferentiated stem cells, reducing the risk of tumour formation. The company's Cellradication technology has the potential to revolutionize stem cell therapies and bring significant improvements to the healthcare industry.
Researchers identified a molecular 'switch' controlling skin cell migration necessary for wound closure and healing. The discovery may hold the key to developing therapeutics that reduce or prevent chronic wounds.
Researchers at A*STAR's Genome Institute of Singapore have developed a novel technique called LoFreq, which allows them to detect microbe and cancer cell mutations in real-time. This breakthrough enables scientists to catch the development of resistance early on and investigate the effectiveness of new drugs.
IBN researchers successfully generated human kidney cells from human embryonic stem cells in vitro, providing a potentially unlimited source of cells for in vitro toxicology testing and regenerative medicine applications. The cells displayed similar gene and protein expression patterns to those isolated from fresh human kidney samples.
Researchers identified lamin A and lamin B receptor proteins as essential for maintaining gene position in the nucleus. Their absence causes genes to malfunction, leading to heart failure, vascular disease, and muscle wasting. This discovery may lead to new treatments for these diseases.
Researchers identified stable haploid strains of Candida albicans, enabling the targeting of individual genes for screening and speeding up the discovery of treatment targets. This breakthrough fills a 100-year gap in understanding this important pathogen's life cycle and may accelerate efforts to cure Candida infections.
Researchers at A*STAR's Genome Institute of Singapore discovered four processes that cause mutations in gastric cancer, including one triggered by bacterial infection. These findings pave the way for diagnostics and targeted therapy, with potential implications for improving treatment outcomes.
Researchers identified 27 genetic loci associated with central corneal thickness, a key factor in blinding eye conditions like glaucoma and keratoconus. This discovery offers new insights into the causes of these diseases, enabling better management and prevention.
Researchers discovered that FAIM can affect cancer cell proliferation and silencing its expression destroys myeloma cells. Higher levels of FAIM correlate with poorer survival outcomes, making it a useful biomarker for multiple myeloma patients.
Researchers have identified telomerase as a cause of chronic inflammation in human cancers, a key underlying factor for many diseases. Developing drugs to target this enzyme may lead to novel treatments that alleviate common ailments such as cancer and diabetes.
Scientists have identified a genetic mutation causing punctate palmoplantar keratoderma (PPPK), a rare skin disorder characterized by thick patches on hands and feet. The AAGAB gene mutation leads to hyperproliferation of skin cells, similar to common warts.
A new study suggests that children and young adults with chronic Hepatitis B Virus infection have a protective immune response, making them suitable treatment candidates. Young patients respond better to treatment and are more able to clear the virus due to their stronger immune system.
A*STAR scientists have identified a potential drug target, miR-138, that can prevent the progression and relapse of glioblastoma multiforme, a deadly form of brain tumour. Depleting this biomarker with antimiR-138 led to complete destruction of cancer cells in vitro.
Researchers at the Singapore Eye Research Institute and Genome Institute of Singapore have identified three new genes linked to PACG, a leading cause of blindness worldwide. The study used genome-wide association analysis and validation experiments to uncover genetic risk factors for the disease.
Researchers at IBN have developed a more powerful and longer lasting fuel cell material using a mixture of gold and copper nanoparticles. The new hybrid material can produce 5 times higher activity and much greater stability than commercial platinum catalysts.
Researchers at A*STAR's Institute of Molecular and Cell Biology have devised a fast and cost-saving way to uncover genetic changes associated with cancer. By studying fruit flies, they identified new 'cooperating' genes that work together to cause aggressive cancer.
Researchers identified a new subset of dendritic cells that play a critical role in activating the immune response against harmful pathogens. The discovery enables better exploitation of targeted vaccine strategies to treat cancer and infection, with significant impact on vaccine design and immunotherapies.
Researchers from A*STAR have identified a novel signalling pathway controlling both obesity and atherosclerosis in mice. The study found that Wip1-deficient mice were resistant to weight gain and atherosclerosis through increased autophagy, highlighting a potential new approach for treating these conditions. Further investigation into ...
A team of researchers identified a unique set of cells at the squamocolumnar junction that express biomarkers found in all forms of invasive cervical cancers linked to HPV. These cells do not regenerate when excised, which has significant implications for diagnosis, prevention, and treatment of cervical cancer.
Researchers at A*STAR's Singapore Immunology Network discovered that long-lived, skin-deep immune cells called Langerhans cells originate from two distinct embryonic sites - the early yolk sac and the foetal liver. These cells play a critical role in initiating protective responses against harmful foreign invaders.
The Singapore-developed H5N1 diagnostic kit can detect all known strains of the virus in a single test within hours. This allows for rapid diagnosis and effective infection control intervention.
A team of scientists has identified the genetic cause of Hamamy syndrome, a rare birth defect marked by abnormal facial features and heart defects. The discovery links the disease to a mutation in the IRX5 gene, which is highly conserved across animals.
Researchers from A*STAR identified the molecular switch Bruton's tyrosine kinase (BTK) that triggers innate immunity and activates potent virus killers, enabling effective responses to dengue and influenza viruses. The discovery paves the way for developing anti-viral drugs targeting BTK.
Researchers at IBN developed a miniaturized biochip, Droplet Array, to study the effect of drugs on cancer stem cells (CSCs). The new technology shows CSCs can survive chemotherapy and drive metastasis, highlighting the need for more effective cancer drugs.
Researchers at A*STAR's Institute of Medical Biology found that reducing SUN1 levels in mouse models doubled the life spans of those with progeria and tripled it for those with Emery-Dreifuss muscular dystrophy. This discovery opens up a possibility for therapeutic use of reduced SUN1 levels for other forms of heart disease.
Researchers at IBN discover engineered human stem cells can target and inhibit tumor growth, prolonging survival in mice with breast tumors. This finding paves the way for innovative stem cell-based therapies, offering a promising alternative to conventional cancer treatment.
Researchers identified a special class of fatty molecules essential for activating immune cells, offering new opportunities for therapeutic interventions. The discovery sheds light on how recognition of these stimulatory fatty molecules by immune cells protects against infection, autoimmune diseases, and cancer.
A new study by A*STAR scientists reveals that the protein TRIM28 plays a crucial role in preserving epigenetic marks during nuclear reprogramming, ensuring proper development of the embryo. The absence of TRIM28 leads to severe developmental defects and multiple pregnancy failures.
Scientists at A*STAR's Singapore Immunology Network have made significant strides in understanding Chikungunya fever, a mosquito-borne disease that can cause severe joint pains. Researchers discovered a direct biomarker, IgG3 antibodies, to identify patients at risk of the more severe form of the disease.
Researchers discovered that high levels of Amd1, an enzyme in the polyamine synthesis pathway, are essential for maintaining embryonic stem cells' (ESCs) self-renewal ability. The study also found that manipulating polyamine levels could help direct ESC differentiation into clinically useful cell types.
Researchers at the Genome Institute of Singapore have made a groundbreaking discovery by mapping the human genome's three-dimensional structure, revealing how genes interact and influence each other. This study sheds light on the complex regulation of gene expression and its implications for understanding human diseases.
Researchers at GIS developed a systematic approach for accurate DNA sequence reconstruction using the Opera algorithm, providing a quality guarantee and scaling to large datasets. This breakthrough enables more complete and accurate draft genomes, driving genetic studies of organisms of interest for human health and other areas.
Scientists have identified two novel susceptibility genes, EDIL3-HAPLN1 and ANO6, related to bone formation and cartilage development. The study also confirms the previously reported association with HLA-B*27 variants, suggesting a complex interplay of immune mechanisms.
Researchers identified a portion of the genome mutated during long-term culture of human embryonic stem cells, which may compromise their utility for regenerative medicine. The study highlights the importance of understanding genetic changes in hESCs and their potential impact on cell therapy applications.
Researchers at A*STAR's Genome Institute of Singapore and Institute of Molecular Biology identify distal airway stem cells as the key to forming new alveoli, paving the way for novel therapies for respiratory diseases. The discovery provides insight into genes and secreted factors that can be used to enhance lung regeneration.
Scientists at A*STAR's IMCB discover that antibodies can directly target intracellular oncoproteins like PRL-3 to suppress cancer growth. This breakthrough finding offers hope for cancer prevention and has the potential to expand the scope of tailor-made antibody therapy and cancer vaccines.
A*STAR scientists have discovered a potential antidote for Ricin and Pseudomonas exotoxin, two deadly toxins responsible for hospital-acquired infections. The study identified ERGIC2 as a therapeutic target, paving the way for developing generic antidotes against these life-threatening toxins.
A*STAR and Agilent launch an integrated drug screening platform, enabling high-throughput screening and automation of compound management and assay plate preparation. The partnership accelerates medical solution development and strengthens biomedical research capabilities.
Researchers discovered that Barrett's esophagus arises from embryonic cells present in all adults, which can rapidly grow and form unusual tissue when the esophagus is damaged by acid reflux. This finding provides a potential target for preventing esophageal cancers.
Researchers have discovered a single communication system that decides the fate of stem cells, paving the way for new stem cell therapies with fewer side effects. The Nodal/Activin pathway can specify a wide range of eventual cell types, offering a major step forward for personalized medicine.
A team of scientists at A*STAR have discovered a way to convert proteins involved in controlling genes into other types of cells by changing a single amino acid. This breakthrough has implications for generating stem cells more efficiently and could help develop treatments for diseases such as diabetes and Parkinson's disease.
Researchers have discovered the genetic fault behind a rare skin cancer that spontaneously heals after growing rapidly. The faulty TGFBR1 gene leads to unusual behavior in these self-healing squamous epithelioma tumors, which may help predict clinical effects of targeted therapies.
Researchers at Singapore Immunology Network (SIgN) and VIVALIS have developed two fully human monoclonal antibodies that can neutralize several Chikungunya strains. These antibodies, generated using VIVALIS' Humalex platform, show promise as a potential treatment for the disease.
Scientists have created the world's first human cell model of progeria, a rare genetic disease causing severe premature ageing in children. The model reveals defects in mesenchymal stem cells and vascular smooth muscle cells that exacerbate symptoms of ageing.
The I2R team achieved high performance in both automatic and interactive search categories, showcasing the effectiveness of their Known-item-Search technology. With a mean inverted rank of 0.454 in automatic search and 0.727 in interactive search, they outperformed other teams and demonstrated the potential of their innovation.